112 related articles for article (PubMed ID: 33408313)
1. In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Watanabe T; Temma Y; Okada J; Yamada E; Saito T; Osaki A; Shimda Y; Matsumoto S; Horiguchi K; Ishida E; Kondo Y; Okada K; Takamizawa T; Nakajima Y; Ozawa A; Okada S; Horigome M; Yamada M
Endocr J; 2021 May; 68(5):599-603. PubMed ID: 33408313
[TBL] [Abstract][Full Text] [Related]
2. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
3. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
4. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.
Kridin K; Amber K; Khamaisi M; Comaneshter D; Batat E; Cohen AD
Immunol Res; 2018 Jun; 66(3):425-430. PubMed ID: 29855994
[TBL] [Abstract][Full Text] [Related]
5. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
6. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
Ihana-Sugiyama N; Sugiyama T; Tanaka H; Ueki K; Kobayashi Y; Ohsugi M
J Eval Clin Pract; 2020 Feb; 26(1):299-307. PubMed ID: 31161662
[TBL] [Abstract][Full Text] [Related]
10. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
11. The association between albuminuria and thyroid antibodies in newly diagnosed type 2 diabetes mellitus patients with Hashimoto's thyroiditis and euthyroidism.
Zhu W; Dong X; Pan Q; Hu Y; Wang G
BMC Endocr Disord; 2020 Nov; 20(1):172. PubMed ID: 33228616
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with dipeptidyl-peptidase 4 inhibitors reduces glycaemic variability and delays insulin initiation in type 2 diabetes: A propensity score-matched cohort study.
Cheung JTK; Yang A; Wu H; Lau ESH; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
Diabetes Metab Res Rev; 2024 Jan; 40(1):e3711. PubMed ID: 37634071
[TBL] [Abstract][Full Text] [Related]
15. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
16. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
[TBL] [Abstract][Full Text] [Related]
18. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
20. Analysis of risk factors for the development of type 2 diabetes mellitus complicated with Hashimoto's thyroiditis.
Han M; Wu H; Yang W; Chen J
BMC Endocr Disord; 2022 Jul; 22(1):173. PubMed ID: 35804367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
